ATE245444T1 - Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen - Google Patents

Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen

Info

Publication number
ATE245444T1
ATE245444T1 AT99906749T AT99906749T ATE245444T1 AT E245444 T1 ATE245444 T1 AT E245444T1 AT 99906749 T AT99906749 T AT 99906749T AT 99906749 T AT99906749 T AT 99906749T AT E245444 T1 ATE245444 T1 AT E245444T1
Authority
AT
Austria
Prior art keywords
asparaginase
treatment
pharmaceutical composition
composition containing
hiv infections
Prior art date
Application number
AT99906749T
Other languages
English (en)
Inventor
Vassilios I Avramis
Lewis Cohen
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE245444T1 publication Critical patent/ATE245444T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT99906749T 1998-02-09 1999-02-09 Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen ATE245444T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7406698P 1998-02-09 1998-02-09
PCT/US1999/002480 WO1999039732A1 (en) 1998-02-09 1999-02-09 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Publications (1)

Publication Number Publication Date
ATE245444T1 true ATE245444T1 (de) 2003-08-15

Family

ID=22117505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906749T ATE245444T1 (de) 1998-02-09 1999-02-09 Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen

Country Status (10)

Country Link
EP (1) EP1053012B1 (de)
JP (1) JP2002502826A (de)
AT (1) ATE245444T1 (de)
AU (1) AU752434B2 (de)
CA (1) CA2319356A1 (de)
DE (1) DE69909747T2 (de)
DK (1) DK1053012T3 (de)
ES (1) ES2203072T3 (de)
WO (1) WO1999039732A1 (de)
ZA (1) ZA991029B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4030200A (en) * 1999-04-02 2000-10-23 Children's Hospital Of Los Angeles Use of asparaginase and glutaminase to treat autoimmune disease and graft versushost disease
AU6894400A (en) * 1999-08-06 2001-03-05 Enzon Pharmaceuticals Inc. Composition and methods for treatment of HIV infection
EP1279406A4 (de) 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd Transporters und arzneimittelabgabesysteme die diese verwenden
CN100544718C (zh) * 2001-04-20 2009-09-30 维奥恩药品公司 化合物在制备抗病毒剂中的用途
BR0215954A (pt) 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
US20080299105A1 (en) * 2004-09-13 2008-12-04 Runtao He Inhibition of Feline Calicivirus
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2015033344A1 (en) * 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
MA51224A (fr) * 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Composés de sulfonamide et leur utilisation
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
CN115671102A (zh) * 2022-11-17 2023-02-03 中国科学院大学 3-ap在制备抑制痘病毒的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2600256B1 (fr) * 1986-06-19 1988-09-16 Inst Nat Sante Rech Med Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
ATE265226T1 (de) * 1997-06-09 2004-05-15 Los Angeles Childrens Hospital Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten

Also Published As

Publication number Publication date
ES2203072T3 (es) 2004-04-01
JP2002502826A (ja) 2002-01-29
DE69909747T2 (de) 2004-04-15
CA2319356A1 (en) 1999-08-12
AU2658499A (en) 1999-08-23
WO1999039732A1 (en) 1999-08-12
DE69909747D1 (de) 2003-08-28
AU752434B2 (en) 2002-09-19
DK1053012T3 (da) 2003-11-17
ZA991029B (en) 1999-09-30
EP1053012A1 (de) 2000-11-22
EP1053012B1 (de) 2003-07-23

Similar Documents

Publication Publication Date Title
BG100455A (en) Hiv protease inhibitors
DE60036961D1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
MXPA04006553A (es) Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
DE69531944D1 (de) Neue hiv-protease-inhibitoren
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
ATE238998T1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
ATE215952T1 (de) Hiv-proteaseinhibitoren
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
ES2132383T3 (es) Inhibidores de proteasa hiv.
EE9700165A (et) Ühendite kombinatsioon, meetod ja farmatseutiline kompositsioon HIV proteaasi ja HIV pöördtranskriptaasi inhibeerimiseks ning HIV infektsiooni vältimiseks või raviks, või AIDS-i või ARC raviks
HK1041444A1 (zh) 用於治療hiv感染的包含peg-天冬酰胺酶的藥物組合物
GB9930768D0 (en) Composition
ATE383161T1 (de) Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
NO20024522D0 (no) Sammensetninger med anti-hiv-aktivitet
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
DK0774969T3 (da) HIV-proteaseinhibitor kombination
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )
TR199902508T2 (xx) HIV proteaz inhibit�rleri.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053012

Country of ref document: EP

REN Ceased due to non-payment of the annual fee